National drug price regulator NPPA is currently evaluating 92 applications for retail price fixation of new fixed dose combinations, Parliament was informed today.
Besides, the National Pharma Pricing Regulator (NPPA) has directed all pharmaceutical companies whose applications for retail price fixation of new FDCs (fixed dose combinations) are pending to submit a declaration signed by the designated authority that the FDC has not been banned by drug control authorities.
"At present, 92 applications for retail price fixation of new FDCs are under examination at NPPA," Minister of State for Chemicals and Fertilisers Hansraj Gangaram Ahir said in a written reply to the Rajya Sabha.
Ceiling and retail prices are fixed only for those formulations, including fixed dose combination (FDCs), which have valid approvals from the Drug Control Authority.
Last month, the Health Ministry had banned 344 FDCs through a gazette notification issued over the weekend.
Various drug firms which were impacted by the ban later approached the court.
